Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Azafaros B.V.
BioCentury | Feb 27, 2025
Guest Commentary
The next rare disease roadblock: American innovation moving ex-U.S.
As regulatory hurdles push early-stage trials out of the U.S., three things FDA can do to bring them back
BioCentury | Oct 24, 2024
Product Development
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals
Therapies aim to enhance lysosomal function to clear cholesterol and glycosphingolipids, mostly via small molecules
BioCentury | Mar 21, 2023
Management Tracks
Debra Yu joins Panacea as partner, COO
Plus: Sonata hires Kite veteran Marincola as CSO and updates from Ascidian, Olink, Azafaros, Akoya and more
BioCentury | Jan 12, 2023
Management Tracks
Azafaros hires Freitag, promotes Landskroner
Plus: KemPharm promotes Guenther and Mickle, and updates from
BioCentury | Jul 1, 2021
Management Tracks
Greune joins CureVac as COO; plus Azafaros names Ultragenyx vet Portolano as CEO and updates from Tenaya, Ambrx, BioSkryb, HiberCell and more
mRNA company CureVac N.V. (NASDAQ:CVAC) hired Malte Greune as COO. He joins from Sanofi-Aventis Deutschland GmbH, where he served for nine years, most recently as general manager and VP of the
BioCentury | Jun 24, 2020
Finance
Expect more company creation by BGV with its €105M fourth fund
Dutch VC BioGeneration Ventures expects to create half of the European start-ups backed by new fund
BioCentury | Feb 8, 2020
Finance
Forbion leads Azafaros’ €25M series A, with rare disease vet as chair
Azafaros believes its oral dual inhibitor approach could treat lysosomal storage disorders that affect the brain
Items per page:
1 - 7 of 7